🇺🇸 FDA

Intelligence · Patent portfolio

Vertex Pharmaceuticals (Australia) Patents

Full USPTO pharma patent portfolio for Vertex Pharmaceuticals (Australia) — grant dates, expiration, and drug cross-links.

Patents
991
Expiring ≤24m
63

Quick answer

Vertex Pharmaceuticals (Australia) has 991 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 63 expire within 24 months — use filters for patent-cliff planning.

Page 1 of 21

  1. US 12421249

    Inhibitors of APOL1 and methods of using same

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12421251

    Cystic fibrosis transmembrane conductance regulator modulating agents

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12384790

    Pteridinone compounds and uses thereof

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12384762

    Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12385013

    Differentiation of pancreatic endocrine cells

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12377252

    Implantation devices, system, and methods

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12371665

    Differentiation of pancreatic endocrine cells

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12350262

    Methods of treatment for cystic fibrosis

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12331057

    Modulators of alpha-1 antitrypsin

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12331334

    Modified urokinase-type plasminogen activator polypeptides and methods of use

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12324802

    Modulators of cystic fibrosis transmembrane conductance regulator

    Expires Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12319693

    Crystalline forms of CFTR modulators

    Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12304900

    Islet cell manufacturing compositions and methods of use

    Expires Mon May 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12281057

    Carboxamides as modulators of sodium channels

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12269831

    Modulators of cystic fibrosis transmembrane conductance regulator

    Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12258333

    N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12251387

    Substituted quinoxalines and benzo[c][1,2,5]oxadiazoles as DNA-PK inhibitors

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12247021

    Substituted tetrahydrofurans as modulators of sodium channels

    Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12214083

    Pharmaceutical composition and administrations thereof

    Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12215355

    Stem cell derived islet differentiation

    Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12194138

    Devices and methods for delivering therapeutics

    Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12195453

    Antiproliferation compounds and uses thereof

    Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12187731

    Compounds useful as inhibitors of ATR kinase

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12186306

    Methods of treatment for cystic fibrosis

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12187698

    Crystalline forms of C21H22Cl2N4O2

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12173337

    Nucleic acid encoding modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use

    Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12173324

    Differentiation of pancreatic endocrine cells

    Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12168009

    Modulators of cystic fibrosis transmembrane conductance regulator

    Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12161674

    CRISPR-CAS9 modified CD34+ human hematopoietic stem and progenitor cells and uses thereof

    Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12134767

    Materials and methods for treatment of hemoglobinopathies

    Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 12129471

    Materials and methods for treatment of human genetic diseases including hemoglobinopathies

    Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12121524

    DNA-PK inhibitors

    Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12116343

    Inhibitors of APOL1 and methods of using same

    Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12116606

    Complement factor I-related compositions and methods

    Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12084438

    GCN2 inhibitors and uses thereof

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12065432

    Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid

    Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12060346

    Inhibitors of APOL1 and methods of using same

    Expires Mon Aug 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12053531

    Materials and methods for treatment of Duchenne Muscular Dystrophy

    Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12049645

    Differentiation of pancreatic endocrine cells

    Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 12043843

    Materials and methods for treatment of hemoglobinopathies

    Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12031150

    Methods, compositions and kits for increasing genome editing efficiency

    Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12006516

    Differentiation of pancreatic endocrine cells

    Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12005127

    DNA-PK inhibitors

    Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11999971

    Stem cell derived islet differentiation

    Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11992506

    Stem cell derived pancreatic islet differentiation

    Expires Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11980633

    Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors

    Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11951206

    Cell housing device

    Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11951212

    Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases

    Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Vertex Pharmaceuticals (Australia) have?

991 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Vertex Pharmaceuticals (Australia) patents expire?

63 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.